Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Raven Biotechnologies

Raven Biotechnologies
1999 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of monoclonal antibody therapeutics created to treat cancer. The company's lead product candidate, RAV12, targets adenocarcinomas and simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them, identifying novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane for the treatment of gastrointestinal and other cancers.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 1140 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Raven Biotechnologies’s full profile, request a free trial.

Raven Biotechnologies Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 17-Jul-2008 00000 Completed Generating Revenue/Not Profitable
9. Merger/Acquisition 01-Mar-2008 Cancelled Clinical Trials - General
8. Convertible Debt 12-Nov-2007 00.00 00000 Completed Generating Revenue/Not Profitable
7. Later Stage VC (Series D) 12-Oct-2005 000.00 00000 Completed Clinical Trials - General
6. Later Stage VC 28-Oct-2004 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 13-Mar-2003 000.00 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series C) 02-Jan-2003 000.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 08-Jan-2001 000.00 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2000 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Raven Biotechnologies Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bear Stearns Health InnoVentures Management Venture Capital Minority 000 0000 000000 0
CIDC Consultants Venture Capital Minority 000 0000 000000 0
China Investment & Development Venture Capital Minority 000 0000 000000 0
Cogene Ventures Venture Capital Minority 000 0000 000000 0
GE Life Science and Technology Finance Corporation Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »